BR112022024729A2 - Inibidores de quinases do receptor do fator de crescimento de fibroblastos - Google Patents

Inibidores de quinases do receptor do fator de crescimento de fibroblastos

Info

Publication number
BR112022024729A2
BR112022024729A2 BR112022024729A BR112022024729A BR112022024729A2 BR 112022024729 A2 BR112022024729 A2 BR 112022024729A2 BR 112022024729 A BR112022024729 A BR 112022024729A BR 112022024729 A BR112022024729 A BR 112022024729A BR 112022024729 A2 BR112022024729 A2 BR 112022024729A2
Authority
BR
Brazil
Prior art keywords
growth factor
factor receptor
fibroblast growth
kinase inhibitors
receptor kinase
Prior art date
Application number
BR112022024729A
Other languages
English (en)
Portuguese (pt)
Inventor
W Kaldor Stephen
Tyhonas John
A Murphy Eric
Kanouni Toufike
D Arnold Lee
Kania Robert
M Cox Jason
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of BR112022024729A2 publication Critical patent/BR112022024729A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022024729A 2020-06-05 2021-06-04 Inibidores de quinases do receptor do fator de crescimento de fibroblastos BR112022024729A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035155P 2020-06-05 2020-06-05
US202063106812P 2020-10-28 2020-10-28
PCT/US2021/035854 WO2021247969A1 (en) 2020-06-05 2021-06-04 Inhibitors of fibroblast growth factor receptor kinases

Publications (1)

Publication Number Publication Date
BR112022024729A2 true BR112022024729A2 (pt) 2023-02-28

Family

ID=78829924

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024729A BR112022024729A2 (pt) 2020-06-05 2021-06-04 Inibidores de quinases do receptor do fator de crescimento de fibroblastos

Country Status (15)

Country Link
US (3) US11345681B1 (enExample)
EP (1) EP4161656A4 (enExample)
JP (1) JP2023529867A (enExample)
KR (1) KR20230035031A (enExample)
CN (1) CN116057045B (enExample)
AU (1) AU2021282596A1 (enExample)
BR (1) BR112022024729A2 (enExample)
CA (1) CA3181162A1 (enExample)
CL (1) CL2022003427A1 (enExample)
CO (1) CO2022018806A2 (enExample)
IL (1) IL298760A (enExample)
MX (1) MX2022015410A (enExample)
SA (1) SA522441624B1 (enExample)
TW (1) TW202210472A (enExample)
WO (1) WO2021247969A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
WO2022042613A1 (zh) * 2020-08-27 2022-03-03 上海和誉生物医药科技有限公司 一种1h-吡唑-4-酰胺衍生物，其制备方法和应用
MX2023008186A (es) * 2021-01-12 2023-07-18 Beijing Innocare Pharma Tech Co Ltd Proceso para preparar (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
WO2023107870A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
EP4444302A4 (en) * 2021-12-08 2025-09-03 Kinnate Biopharma Inc SOLID STATE FORMS OF AN FGFR INHIBITOR
AU2022407439A1 (en) * 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor
CN115232074A (zh) * 2022-08-22 2022-10-25 湖南复瑞生物医药技术有限责任公司 一种1-烷基取代-2-甲基-5-溴苯并咪唑的合成方法
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds
IT202400013555A1 (it) * 2024-06-13 2025-12-13 Iama Therapeutics S R L Derivati benzoimidazolici come inibitori di nkcc1

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5886022A (en) 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
SI9600371B (sl) 1996-12-18 2005-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Etilidenski derivati tricikličnih karbapenemov
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
DE60221875T2 (de) 2001-11-02 2007-12-20 Glaxo Group Ltd., Greenford 4-(6-gliedrige)-heteroaryl-acyl-pyrrolidinderivate als hcv-inhibitoren
US20050043545A1 (en) 2001-11-02 2005-02-24 Gianpalol Bravi 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
PT1519939E (pt) 2002-07-05 2010-02-10 Targacept Inc Compostos n-arildiazaspirocíclicos e métodos para a sua preparação e utilização
US7754188B2 (en) 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
FR2860431A1 (fr) 2003-10-02 2005-04-08 Oreal Composition capillaire ou de mascara contenant un compose azoique, son utilisation pour stimuler ou induire la pousse des cheveux ou des cils et/ou freiner leur chute
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
MXPA06011423A (es) * 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
AU2005231440B9 (en) 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
JP2008510711A (ja) 2004-08-20 2008-04-10 ターガセプト，インコーポレイテッド 嗜癖治療におけるｎ−アリールジアザスピラ環状化合物の使用
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7732607B2 (en) 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
EP2007757B1 (en) 2006-04-13 2012-10-03 Vertex Pharmceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
CA2652816A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009538305A (ja) 2006-05-23 2009-11-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
WO2008012010A1 (en) 2006-07-27 2008-01-31 Ucb Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
MX347085B (es) 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
EP2036906A1 (de) 2007-09-05 2009-03-18 Bayer Schering Pharma Aktiengesellschaft Azaindole als Inhibitoren der löslichen Adenylatzyklase
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EA201001205A1 (ru) 2008-01-24 2011-04-29 Юсб Фарма, С.А. Соединения, содержащие циклобутоксигруппу
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
EP2401273A1 (en) 2009-02-27 2012-01-04 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
HRP20151258T1 (hr) 2009-08-07 2016-02-26 Chugai Seiyaku Kabushiki Kaisha Derivat aminopirazola
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2794181A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
US8735386B2 (en) 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US9295754B2 (en) 2011-02-24 2016-03-29 Emory University Noggin inhibitory compositions for ossification and methods related thereto
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012154608A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive mtor and pi3 kinase inhibitors and uses thereof
WO2013025498A1 (en) 2011-08-12 2013-02-21 Schubert David R Neuroprotective polyphenol analogs
WO2013025484A1 (en) 2011-08-12 2013-02-21 Lapchak Paul A Polyphenol analogs to treat ischemia
BR112014009037A2 (pt) 2011-10-18 2017-05-09 Syngenta Participations Ag derivados pirazol microbicidas
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
EP2615083A1 (en) 2012-01-10 2013-07-17 Studiengesellschaft Kohle mbH Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst
AU2013210403B2 (en) 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
US20130303509A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
MX2014013758A (es) 2012-05-11 2015-02-05 Abbvie Inc Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
EP2852585A1 (en) 2012-05-11 2015-04-01 AbbVie Inc. Nampt inhibitors
WO2014045305A1 (en) 2012-09-21 2014-03-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2014158943A1 (en) 2013-03-13 2014-10-02 Avon Products, Inc Tyrosinase inhibitors
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
US20160008493A1 (en) 2013-03-15 2016-01-14 The Johns Hopkins University Radioactive substrates for aldehyde dehydrogenase
EP2999345B1 (en) 2013-05-22 2022-08-10 Curza Global LLC Compositions and methods comprising a polyamine
CN105555785B (zh) 2013-06-18 2019-03-01 4Sc股份公司 作为dyrk激酶抑制剂的2，3-二氢苯并呋喃-5-基化合物
WO2014206343A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
US20160368897A1 (en) 2013-06-28 2016-12-22 Emory University Pyrazoline Dihydroquinolones, Pharmaceutical Compositions, and Uses
JP6084292B2 (ja) * 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
DK3023100T3 (da) 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
CA2918534A1 (en) 2013-07-25 2015-01-29 Fondazione Telethon Inhibitors of fapp2 and uses thereof
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
CN104341425B (zh) * 2013-08-08 2018-11-02 上海医药集团股份有限公司 氘代乙炔衍生物、其药物组合物及应用
WO2015031608A1 (en) 2013-08-28 2015-03-05 Vanderbilt University Substituted indole mcl-1 inhibitors
WO2015039613A1 (zh) 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
RU2650512C2 (ru) 2013-09-18 2018-04-16 Бейджин Ханми Фармасьютикал Ко., Лтд. Соединение, ингибирующее активности киназ ВТК и/или JAK3
WO2015073833A1 (en) 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
EP3076974A1 (en) 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
WO2015134357A1 (en) 2014-03-03 2015-09-11 Emory University Modulators of insulin receptor
US20160008366A1 (en) 2014-07-14 2016-01-14 Pharmacyclics Llc Btk inhibitors for the treatment of cns malignancies
CN112898308B (zh) 2014-08-15 2026-08-07 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN107108512B (zh) 2014-10-10 2021-05-04 基因泰克公司 治疗性化合物及其用途
CN107406429B (zh) 2015-01-09 2021-07-06 基因泰克公司 哒嗪酮衍生物及其在治疗癌症中的用途
US10434103B2 (en) 2015-03-31 2019-10-08 Taiho Pharmaceutical Co., Ltd. Crystal of 3,5-disubstituted benzene alkynyl compound
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US11476426B2 (en) 2016-02-03 2022-10-18 Sfc Co., Ltd. Organic light emitting compounds and organic light emitting devices including the same
CN107513068A (zh) * 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
CN107698593A (zh) 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN110139865B (zh) * 2016-12-29 2022-02-18 石药集团中奇制药技术（石家庄）有限公司 Fgfr抑制剂
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US20200385364A1 (en) 2017-01-26 2020-12-10 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
TW201902875A (zh) 2017-03-15 2019-01-16 美商亞瑟尼克斯公司 聯芳基哌啶醯胺化合物及其使用方法
CN108623562A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种喹啉酮生物碱类化合物及其制备方法和应用
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
CN108658974A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种内酰胺类化合物及其制备方法和用途
CN108690016B (zh) 2017-04-11 2022-08-12 广东东阳光药业有限公司 吡唑并吡啶类化合物及其用途
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019023448A1 (en) 2017-07-26 2019-01-31 Emory University INHIBITORS OF NADPH OXIDASE AND THEIR USE
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
CN111247150B (zh) 2017-08-15 2022-11-08 石药集团中奇制药技术（石家庄）有限公司 Fgfr抑制剂及其医药用途
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CN110117285B (zh) 2018-02-07 2023-02-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
US20210154188A1 (en) 2018-04-02 2021-05-27 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
TW202021969A (zh) 2018-05-31 2020-06-16 南韓商Ｃ＆Ｃ新藥研究所 雜環衍生物及其用途
TWI848954B (zh) 2018-06-13 2024-07-21 英屬開曼群島商百濟神州有限公司 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
JP2022533939A (ja) 2019-05-17 2022-07-27 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤
TW202128174A (zh) 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
EP4161657A1 (en) 2020-06-05 2023-04-12 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
EP4444302A4 (en) 2021-12-08 2025-09-03 Kinnate Biopharma Inc SOLID STATE FORMS OF AN FGFR INHIBITOR
WO2023107870A1 (en) 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407439A1 (en) 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor

Also Published As

Publication number Publication date
CL2022003427A1 (es) 2023-06-30
AU2021282596A1 (en) 2023-01-19
EP4161656A4 (en) 2024-06-19
US20230078839A1 (en) 2023-03-16
CA3181162A1 (en) 2021-12-09
WO2021247969A1 (en) 2021-12-09
US20250333399A1 (en) 2025-10-30
US11345681B1 (en) 2022-05-31
KR20230035031A (ko) 2023-03-10
CN116057045B (zh) 2026-06-09
MX2022015410A (es) 2023-03-13
SA522441624B1 (ar) 2025-04-10
IL298760A (en) 2023-02-01
US12331039B2 (en) 2025-06-17
CO2022018806A2 (es) 2022-12-30
TW202210472A (zh) 2022-03-16
JP2023529867A (ja) 2023-07-12
CN116057045A (zh) 2023-05-02
EP4161656A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
SA522441624B1 (ar) مثبطات إنزيمات كيناز مستقبل عامل نمو الأرومة الليفية
SA522441639B1 (ar) Egfr مثبطات تفارغية وطرق استخدامها
BR112021023824A2 (pt) Inibidor de proteína quinase dependente de dna
CO2022006712A2 (es) Inhibidores de las cinasas raf
JOP20210154B1 (ar) مثبطات kif18a
MX386089B (es) Compuesto heterociclico utilizado como inhibidor de fgfr.
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
MX387394B (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
BR112016012734A8 (pt) composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto
BR112016028273A2 (pt) derivados radiorrotulados de composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pira¬zol[1,5-a]pirimidin-3-carboxamida úteis como inibidor de atr cinase, a preparação do referido composto e diferentes formas sólidas do mesmo
JOP20230170A1 (ar) مثبطات cdk2 وطرق لاستخدامها
EA202091475A1 (ru) ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
ZA202304734B (en) Alpha protein kinase 1 inhibitors and methods of use
CO2024009144A2 (es) Inhibidores de cinasa met
BR112022009086A2 (pt) Inibidores alostéricos de egfr e métodos de uso dos mesmos
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase
MX387785B (es) Compuestos heteroarilo y su uso como farmacos terapeuticos.
BR112022022367A2 (pt) Derivados e síntese de ácido borônico, formas polimórficas e usos terapêuticos dos mesmos
AR131414A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
AR131413A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
BR112021020405A2 (pt) Benzo- e pirido-pirazóis como inibidores de proteína quinase
IL309064A (en) Heteroaryl compounds as inhibitors of tyk2, composition and application thereof
CO2025012210A2 (es) Polimorfo como inhibidor de la proteína quinasa mek, método de preparación y uso del mismo
AR122550A1 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblatos